Ultragenyx increases proposed IPO price range to $19 to $20; deal size is now $94 million

Comment

Shutterstock photo

Ultragenyx Pharmaceutical, a clinical-stage biotech developing treatments for rare metabolic genetic diseases, raised the price range for its upcoming IPO on Wednesday. The Novato, CA-based company now plans to raise $94 million by offering 4.8 million shares at a price range of $19 to $20, up from a range of $14 to $17. At the midpoint of the revised range, Ultragenyx Pharmaceutical will raise 26% more than previously anticipated. Ultragenyx Pharmaceutical, which was founded in 2010, plans to list on the NASDAQ under the symbol RARE. Ultragenyx Pharmaceutical initially filed confidentially on 10/4/2013. J.P. Morgan and Morgan Stanley are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com